This may indicate that control of tumor growth is dominated by targeted therapies and that a constant influence of the BRAF/VEGFA targeting on TME should be required to exploit the best efficacy of anti‐PD‐1 treatment. The gene discussed is BRAF; the disease is neoplasm.